Skip to main content


We're creating a new version of this page. See preview

  • Poster presentation
  • Open Access

Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting

  • 1,
  • 2,
  • 3,
  • 4 and
  • 5
Clinical and Translational Allergy20133 (Suppl 1) :P13

  • Published:


  • Asthma
  • Clinical Study
  • Corticosteroid
  • Asthma Control
  • Oral Corticosteroid


Patients with severe allergic asthma (SAA) are often inadequately controlled despite available treatments including high-dose inhaled corticosteroids and long-acting β2-agonists. Use of oral corticosteroids (OCS) in SAA patients may not achieve full asthma control, and leads to significant long-term side effects. Omalizumab is a recombinant humanized monoclonal anti-immunoglobulin E (IgE) antibody approved in the European Union as an add-on therapy for patients with SAA. In clinical studies, omalizumab has been shown to reduce OCS use. Here we report the effect of omalizumab treatment on OCS maintenance use for up to 24 months in patients with SAA in the real-world eXpeRience registry.


eXpeRience was a 2-year, multicentre, non-interventional, single-arm, observational registry initiated to collect data from patients receiving omalizumab for uncontrolled SAA. Data were collected on OCS maintenance use at baseline, Month 12, and Month 24. Parameters assessed were incidence of OCS maintenance use, total daily OCS dose and change from baseline, and time to reduction in OCS dose or stopping therapy.


At Month 24, 49% of the patients on OCS had discontinued their use and 20% had reduced their OCS dosage, this was incremental from Month 12. OCS maintenance use at baseline, Month 12 and Month 24 is summarized in Table 1.

Table 1


Baseline N=916

12 months N=734

24 months N=643

Patients on OCS maintenance monotherapy, n (%)

262 (28.6)

118 (16.1)

91 (14.2)

Mean (SD) total daily OCS dose*, mg

15.49 (14.01)a

7.68 (10.94)b

5.77 (8.89)c

Mean (SD) reduction from baseline in total daily dose, mg


7.89 (13.77)b

9.95 (15.58)c

Patients with alteration in total OCS dose, n (%)




77 (40.7)b

82 (48.8)c



31 (16.4)b

34 (20.2)c

no change


76 (40.2)b

48 (28.6)c



5 (2.6)b

4 (2.4)c

Mean (SD) time to either reduction or discontinuation of OCS, days


198.5 (114.29)d

291.2 (210.86)e

* OCS dose was reported in prednisolone equivalent dose as mg per day. OCS oral corticosteroid; SD standard deviation; n number of patients who received OCS at baseline and who provided OCS information at 12 months and 24 months (an=246; bn=189; cn=168; dn=108; en=116).


Omalizumab reduced the need for maintenance OCS use in patients with severe allergic (IgE-mediated) asthma in a real-world setting. Reduction in OCS maintenance use may reflect better asthma control and decreases the risk of long-term morbidity of corticosteroid exposure.

Authors’ Affiliations

St Franciscus Gasthuis, Department of Pulmonary Medicine, the Netherlands
Thomayer Hospital, Charles University, Department of Pulmonary Disease, Czech Republic
Novartis Pharmaceuticals UK Limited, Clinical Development, UK
Novartis Pharma AG, Clinical Development, Switzerland
Novartis Pharmaceuticals Corporation, Clinical Development, USA


© Braunstahl et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.